Analyst consensus rating
Traws Pharma Analyst Rating: Hold
TRAW is rated Hold by 1 analysts with a $1.00 target. As of 2026-08-27.
Direct answer
Traws Pharma's consensus rating is Hold.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.00.
Forecast evidence checked August 27, 2026.
Get free Traws Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.60
- Average price target
- $1.00
- High price target
- $1.00
- Low price target
- $1.00
- Low target gap
- +66.4%
- Target upside
- +66.4%
- High target gap
- +66.4%
- Target range width
- 0%
- Consensus rating
- Hold
- Analysts
- 1
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Traws Pharma?
Traws Pharma has a verified Hold consensus. The same dataset has an average price target of $1.00.
How far are Traws Pharma's low and high targets from the recorded price?
The low target implies +66.4%, while the high target implies +66.4%.
How many analysts are included in Traws Pharma's consensus?
The verified consensus includes 1 analysts.
How is Traws Pharma's target upside or downside calculated?
The average target of $1.00 is divided by the recorded price of $0.60, then one is subtracted to produce +66.4%. This does not guarantee a future return.
When was Traws Pharma's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.